Privacy Preference Center

Your Privacy

Information may be obtained or stored in your browser by cookies when you access the Website. This information is related to the user, the user settings or device. It is primarily used to ensure the site functions as expected by the user. We respect your right to privacy. Therefore, you can select to not allow some types of cookie. Please click on the different category headings to check the details and then change our default settings.

More Information

Strictly Necessary Cookies

Strictly Necessary Cookies are cookies that are essential for this site to function properly. Strictly Necessary Cookies do not store information that can identify individuals. Strictly Necessary Cookies are used to view this site. Therefore, you cannot refuse the use of Strictly Necessary Cookies from these cookie settings. However, you can refuse the use of Strictly Necessary Cookies from the settings of your browser at any time. Please note that parts of the site may not function if you refuse the use of Strictly Necessary Cookies.

This site uses the following Strictly Necessary Cookies.

Cookie name: gdprCookieEn

  • Purpose:To control the display for the confirmation of cookies on this site
  • Term of validity:1 year

Cookie name: optGA

  • Purpose:To opt out/opt in of (disable/enable) Google Analytics
  • Term of validity:1 year

Cookie name: optPardot

  • Purpose:To opt out/opt in of (disable/enable) Pardot
  • Term of validity:1 year

Google Analytics

You can refuse cookies other than the Strictly Necessary Cookies from the following settings. If you refuse the use of these cookies, we will not know even if you visit this site.

Cookies used

_ga,_ga_{container-id},_gid,_gcl_au

  • Purpose:To statistically research and analyze the usage situation of this Website
  • Term of validity:1 year

Pardot

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site.

All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.

Pardot Cookies used

pi_<accountid>,visitor_id<accountid>,visitor_id<accountid>-hash
Ipv<accountid>, pardot

  • Purpose:To provide useful information on products and services
  • Term of validity:1 year

Japanese

Pharmaceuticals

Nippon Kayakuʼs efforts towards cancer treatment have provided numerous products since the launch of BLEO™.

A large lineup of cancer-related products and accumulation of information as well as know-how are our strong points. In the cancer-related field, we aim to contribute to society through improved medical care by promoting innovations in our proprietary technologies and by providing a stable supply of and information about high quality pharmaceutical products. We do this by stationing cancer-specialist medical representatives throughout Japan, setting up Medical Information Service Centers, where we respond to inquiries from medical professionals and others, and preparing a framework that can deliver information to medical institutions about correct drug use for assisting in medical treatment.

医薬品

Introduction of Main Products

Anti-cancer drugs

Nippon Kayaku's involvement with anti-cancer drugs dates back to 1969, when it released bleomycin. After that, the company has continued its research and development of therapeutic agents for the improvement of cancer treatment. As of September 2024, Nippon Kayaku has launched 51 anti-cancer drugs and cancer-related drugs, including generics.

History of anti-cancer and cancer-related drugs at Nippon Kayaku

The company's strength lies in its extensive line of anti-cancer drugs and expertise.

医薬品

（as of January, 2025）

Cancer-related drugs

In addition to anti-cancer drugs, Nippon Kayaku also researches, develops, and sells other drugs used in cancer treatment. These typically include a pain relief drug to relieve the pain caused by metastatic bone cancer.

Biosimilars

Nippon Kayaku aims to make further contributions to patients, their families, and medical professionals through the rapid commercialization of biosimilar pharmaceuticals, which are playing a major role in the treatment of cancer and Autoimmune disease. By providing a wide range of biosimilars, the company hopes to help realize a society where everyone has access to high quality medical care, at any place and time.

History of Biosimilars at Nippon Kayaku

医薬品

（as of September, 2024）

Generic drugs

Nippon Kayaku is also engaged in the development of generic drugs. Since there are a large number of drugs involved in cancer treatment, including anti-cancer and anti-emetic drugs, in these generic drugs, the company has worked to further expand its lineup of cancer medications.

Other pharmaceuticals

In addition to cancer-related drugs, Nippon Kayaku is engaged in the development and manufacturing of other pharmaceuticals, such as cardiovascular treatments.

Related Information

  • MINK Web (Japanese site)
    Information site for medical professionals (only for medical professionals)
  • For patients and family members (Japanese site)
    Introducing the website related to Nippon Kayaku's products to patients and family members.

Our Business

PageTop
Our Business
R&D
Corporate Information
Global Netowork
Investor Relations
Integrated report
Sustainability